» Articles » PMID: 35046764

Impact of a Novel Strategy for Critical Values Communication for the Management of Patients Treated with Clozapine

Overview
Journal EJIFCC
Specialty Biochemistry
Date 2022 Jan 20
PMID 35046764
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Clozapine is an antipsychotic drug used to treat resistant schizophrenia and other disorders. Based on the actual Spanish legislation, patients treated with clozapine must undergo periodical haematological examinations and treatment should be reviewed when the haemogram shows either a leukocyte count of ≤ 3500/mm or neutrophil count < 2000/mm. An automatic notification system has been developed to optimize patient management and it's utility was assessed following the implementation of the new system.

Material And Methods: When clozapine (CLO) laboratory test request was made, a reflex complete blood count test was also done. An automatic e-mail was sent by the laboratory information system to the physician when a CLO was ordered and low leukocyte or neutrophil counts were detected, or when a patient with an ordered CLO test did not attend the laboratory for blood drawing.

Results: For patients with haemogram alterations, the time to take clinical action was significantly decreased from 23 to 7 days ( = 0.02). Moreover, the adherence to Spanish Agency of Drugs and Sanitary Devices recommendations significantly increased from 45% to 76% ( = 0.02). For not attending patients, the days out of control decreased from 29 to 12 days, although it was not statistically significant ( = 0.06).

Conclusions: This strategy has allowed the compliance of legal requirements, the improvement of patient safety, and the optimisation of clinical and laboratory procedures.

References
1.
Piva E, Plebani M . Interpretative reports and critical values. Clin Chim Acta. 2009; 404(1):52-8. DOI: 10.1016/j.cca.2009.03.028. View

2.
Dighe A, Jones J, Parham S, Lewandrowski K . Survey of critical value reporting and reduction of false-positive critical value results. Arch Pathol Lab Med. 2008; 132(10):1666-71. DOI: 10.5858/2008-132-1666-SOCVRA. View

3.
Pons A, Undurraga J, Batalla A, Bernardo M . [Clozapine and agranulocitosis in Spain: do we have a safer population? A 5-year hematologic follow-up]. Rev Psiquiatr Salud Ment. 2012; 5(1):37-42. DOI: 10.1016/j.rpsm.2011.11.003. View

4.
Hippius H . A historical perspective of clozapine. J Clin Psychiatry. 1999; 60 Suppl 12:22-3. View

5.
Leucht S, Corves C, Arbter D, Engel R, Li C, Davis J . Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2008; 373(9657):31-41. DOI: 10.1016/S0140-6736(08)61764-X. View